Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Phenazopyridine Hydrochloride
Brand Name
Vexia Maximum Strength Urinary Pain Relief
Generic Name
Phenazopyridine Hydrochloride
Active Ingredient
PhenazopyridineCategory
Other
Salt Form
Hydrochloride
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 99.5 mg/1 | TABLET | ORAL | 10956-703 |
Detailed information about Vexia Maximum Strength Urinary Pain Relief
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Vexia Maximum Strength Urinary Pain Relief, you must consult a qualified healthcare professional.
Phenazopyridine is a urinary tract analgesic used for the symptomatic relief of pain, burning, and urgency caused by irritation of the lower urinary tract mucosa. It is an azo dye that exerts a local anesthetic effect on the urinary lining.
The standard adult dosage for phenazopyridine hydrochloride is designed to provide maximum relief while minimizing the risk of metabolite accumulation.
The safety and efficacy of phenazopyridine in the pediatric population have not been extensively studied in controlled clinical trials.
Because phenazopyridine is cleared by the kidneys and acts within the urinary tract, renal function is the most important factor in dosing safety.
While the liver metabolizes phenazopyridine, specific dosing guidelines for hepatic impairment are not well-established. However, since p-aminophenol (a toxic metabolite) is produced in the liver, patients with severe liver disease should be monitored closely for signs of toxicity.
Geriatric patients often have undiagnosed age-related declines in renal function (reduced glomerular filtration rate). Healthcare providers typically perform a baseline creatinine clearance check before recommending phenazopyridine to elderly patients to avoid drug accumulation.
If a dose is missed, it should be taken as soon as the patient remembers, provided it is taken with food. If it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never double the dose to "catch up," as this increases the risk of renal stress and methemoglobinemia.
An overdose of phenazopyridine is a medical emergency. Signs of toxicity include:
Emergency measures include gastric lavage and the administration of methylene blue (1-2 mg/kg intravenously) for severe methemoglobinemia. Oxygen therapy and blood transfusions may be required in cases of severe hemolysis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or extend the duration of use without medical guidance.
By far the most common and expected side effect of phenazopyridine is a vivid reddish-orange discoloration of the urine. This occurs in nearly 100% of patients because phenazopyridine is an azo dye. While this can be alarming to patients who are not forewarned, it is a benign (harmless) pharmacological effect of the drug.
Other common side effects include:
> Warning: Stop taking Phenazopyridine and call your doctor immediately if you experience any of these serious reactions.
Phenazopyridine is strictly intended for short-term use (maximum of 2 days). Prolonged use (weeks or months) has been associated with:
No FDA black box warnings currently exist for Phenazopyridine. However, the FDA-approved labeling carries strong "Precautions" regarding its use in patients with renal impairment and the strict limitation of 48-hour therapy when used with antibiotics.
Report any unusual symptoms, particularly skin color changes or severe fatigue, to your healthcare provider immediately.
Phenazopyridine is a symptom-management tool, not a cure. The most critical safety point is that it must not be used as a substitute for antibiotic treatment. Because it is highly effective at numbing the pain of a UTI, patients may mistakenly believe their infection is gone and stop taking their antibiotics. This can lead to a more severe kidney infection (pyelonephritis) or sepsis.
Additionally, patients must be aware that the orange-red dye will stain not only urine but also clothing, bedding, and soft contact lenses. The stains on fabrics are often permanent. Using a sanitary pad may help prevent staining of undergarments.
No FDA black box warnings for Phenazopyridine. However, clinical guidelines from the American Urological Association emphasize the importance of limiting use to 48 hours to prevent the masking of symptoms.
For short-term use (2 days), intensive monitoring is usually not required for healthy adults. However, for certain patients, the following may be necessary:
Phenazopyridine may cause dizziness or blurred vision in some individuals. Patients should observe how the medication affects them before driving or operating heavy machinery. If dizziness occurs, these activities should be avoided.
There is no direct chemical interaction between phenazopyridine and alcohol. However, alcohol is a bladder irritant and can worsen the symptoms of a UTI (frequency and urgency). Furthermore, both alcohol and phenazopyridine metabolites are processed by the liver; excessive alcohol consumption may increase the risk of gastrointestinal upset or liver stress while taking this medication.
There is no withdrawal syndrome associated with phenazopyridine, and it does not require tapering. Patients should stop taking the drug as soon as their symptoms are managed or after 48 hours of use, whichever comes first. If symptoms return after discontinuation, it is vital to contact a healthcare provider to ensure the underlying infection is being treated correctly.
> Important: Discuss all your medical conditions, especially kidney or blood disorders, with your healthcare provider before starting Phenazopyridine.
While phenazopyridine does not have many absolute drug-drug contraindications, it should never be used with other medications that are known to cause methemoglobinemia or significant hemolysis in susceptible individuals.
Phenazopyridine is notorious for interfering with laboratory tests that rely on colorimetric analysis (tests that use color changes to determine results).
For each major interaction, the management strategy is typically to inform the laboratory that the patient is taking phenazopyridine so that alternative testing methods (such as microscopic examination) can be used.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are scheduled for any lab work.
Phenazopyridine must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a physician include:
Patients who are allergic to other azo dyes (used in food coloring or other medications) may have a higher risk of an allergic reaction to phenazopyridine. There is also some evidence of cross-sensitivity with certain "sulfa" drugs, although this is not universally observed. If a patient has a history of severe drug allergies, the first dose of phenazopyridine should be taken under observation.
> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and any genetic blood disorders, before prescribing Phenazopyridine.
FDA Pregnancy Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women. However, because phenazopyridine is an azo dye and its metabolites can cross the placenta, it should be used during pregnancy only if clearly needed. Most clinicians prefer using increased fluid intake and prompt antibiotic therapy alone for UTIs in pregnant women unless the pain is debilitating. There is no evidence of teratogenicity (birth defects) at standard doses.
It is not known whether phenazopyridine or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and the potential for serious adverse reactions in nursing infants (such as hemolytic anemia) exists, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Phenazopyridine is generally not recommended for children under the age of 6. For children aged 6-12, it is occasionally used for short-term (2-day) relief, but the dosing must be strictly weight-based (typically 12 mg/kg/day). Parents must be warned about the urine discoloration to prevent unnecessary anxiety. Long-term effects on growth and development have not been studied.
Elderly patients are at the highest risk for adverse effects from phenazopyridine. This is primarily due to the natural decline in renal function that occurs with age. Even if a serum creatinine level appears "normal," the actual glomerular filtration rate (GFR) may be low. Geriatric patients are more likely to develop methemoglobinemia and skin pigmentation changes. Healthcare providers often use a lower dose or a shorter duration in this population.
As established, renal impairment is a major concern.
Patients with hepatic impairment should be monitored for signs of jaundice or increased liver enzymes. Since the liver is responsible for the initial breakdown of the drug, liver failure can lead to unpredictable blood levels of the parent compound and its metabolites.
> Important: Special populations, particularly the elderly and those with kidney issues, require individualized medical assessment and should never take this medication without professional guidance.
Phenazopyridine hydrochloride is an azo dye (1-Phenylazo-2, 6-diaminopyridine monohydrochloride). Its primary pharmacological action is a local anesthetic effect on the mucosa of the urinary tract. While the exact molecular target (e.g., specific sodium channels or receptors) is not fully defined, it is categorized as a topical analgesic that acts only when excreted into the urine. It does not have any systemic analgesic properties and does not affect the inflammatory response or bacterial growth. Its action is purely palliative, meaning it treats symptoms but not the cause of the irritation.
The onset of the analgesic effect typically occurs within 1 to 2 hours after oral administration, coinciding with the appearance of the dye in the urine. The duration of effect for a single dose is approximately 6 to 8 hours, which necessitates the three-times-daily dosing schedule. There is no evidence of the development of pharmacological tolerance with short-term use, but the risk of toxicity increases significantly if the drug is used beyond the recommended 48-hour window.
| Parameter | Value |
|---|---|
| Bioavailability | Rapidly absorbed (Exact % unknown) |
| Protein Binding | Minimal to moderate |
| Half-life | 8-12 hours (prolonged in renal impairment) |
| Tmax | 1.5 - 2 hours |
| Metabolism | Hepatic (Hydroxylation and azo-reduction) |
| Excretion | Renal (90% within 24 hours; 40% unchanged) |
Phenazopyridine belongs to the therapeutic class of Urinary Tract Analgesics. It is unique in this class, as most other urinary medications are either anti-infectives (antibiotics), antispasmodics (like oxybutynin), or alpha-blockers (like tamsulosin). It is often referred to as an "Azo-dye analgesic."
Common questions about Vexia Maximum Strength Urinary Pain Relief
Phenazopyridine is primarily used to relieve the symptoms of lower urinary tract irritation, such as pain, burning, and the frequent or urgent need to urinate. These symptoms are most commonly caused by urinary tract infections (UTIs), but they can also result from surgery, injury, or medical procedures like catheterization. It is important to understand that this medication is an analgesic (pain reliever) and not an antibiotic; it does not treat the underlying infection itself. Healthcare providers typically prescribe it for only the first two days of UTI treatment to help the patient remain comfortable while the antibiotics begin to work. Using it longer than two days is generally discouraged as it can mask symptoms if the infection is not responding to treatment.
The most common and expected side effect is a vivid reddish-orange discoloration of the urine, which occurs because the drug is a dye. This effect is harmless but can stain clothing and soft contact lenses permanently. Many patients also experience gastrointestinal issues such as nausea, vomiting, or stomach cramps, particularly if the medication is taken on an empty stomach. Headaches and occasional dizziness are also frequently reported by patients during the short course of treatment. If you notice a yellowish tint to your skin or the whites of your eyes, you should stop the medication immediately and contact a doctor, as this could indicate a more serious issue with your kidneys or liver.
While there is no known direct chemical interaction between alcohol and phenazopyridine, it is generally recommended to avoid alcohol while treating a urinary tract infection. Alcohol is a known bladder irritant and can significantly worsen the symptoms of urgency and frequency that you are trying to treat. Furthermore, alcohol can contribute to dehydration, which may slow the flushing of bacteria and medication through your urinary system. Both substances are processed by the liver, so avoiding alcohol can also reduce the metabolic load on your body during illness. Always consult your healthcare provider for specific advice regarding alcohol consumption and your medications.
Phenazopyridine is classified by the FDA as Pregnancy Category B, meaning that animal studies have not shown a risk to the fetus, but there are no adequate, well-controlled studies in pregnant humans. Because the drug and its metabolites can cross the placenta, it is typically only used during pregnancy if the potential benefits clearly outweigh the risks. Most doctors prefer to treat UTIs in pregnant women with antibiotics and increased fluid intake first. If you are pregnant or planning to become pregnant, you must discuss the use of this medication with your obstetrician. It should be used for the shortest duration possible if prescribed during pregnancy.
Phenazopyridine typically begins to work within 1 to 2 hours after the first dose is taken. You will know the medication is in your system when you notice your urine changing to an orange or reddish color. The maximum pain-relieving effect is usually felt after the second or third dose as the concentration of the drug in the urinary tract stabilizes. Because it works locally on the lining of the bladder and urethra, its onset is relatively fast compared to many systemic medications. If you do not feel any relief after 24 hours of treatment, you should contact your healthcare provider to re-evaluate your condition.
Yes, you can stop taking phenazopyridine suddenly without any risk of withdrawal or physical dependence. In fact, the medication is intended for very short-term use, typically no more than two consecutive days. Once your urinary pain and burning have subsided, or once you have completed the 48-hour window recommended by your doctor, you should stop taking it. However, if you are taking phenazopyridine alongside an antibiotic for an infection, you must continue taking the antibiotic for the full duration prescribed, even if the pain is gone. Stopping your antibiotic early can lead to a return of the infection and antibiotic resistance.
If you miss a dose of phenazopyridine, you should take it as soon as you remember, provided you can take it with food to avoid stomach upset. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects and potential toxicity. Since the medication is only taken for a short period (usually 2 days), missing a dose may result in a temporary return of urinary discomfort. Consistency is important for maintaining symptom relief during the initial phase of infection treatment.
There is no clinical evidence to suggest that phenazopyridine causes weight gain. Because the medication is only used for a maximum of two days, it does not have enough time to affect metabolic processes or fat storage in a way that would lead to a change in body weight. If you experience swelling or sudden weight gain while taking this medication, it could be a sign of a serious side effect like kidney impairment or an allergic reaction, rather than typical weight gain. In such cases, you should seek medical attention immediately. Always report unexpected physical changes to your healthcare provider.
Phenazopyridine can be taken with most common antibiotics used for UTIs, such as ciprofloxacin or trimethoprim/sulfamethoxazole. However, it can interact with certain medications that affect the blood or kidneys, such as dapsone or local anesthetics like prilocaine. It is also known to interfere with various laboratory tests, including urine glucose and bilirubin tests, because of its strong color. You should always provide a full list of your current medications and supplements to your doctor or pharmacist before starting phenazopyridine. This ensures that no potential interactions will compromise your safety or the accuracy of your medical tests.
Yes, phenazopyridine is widely available as a generic medication and is also sold under various brand names such as Pyridium, AZO Urinary Pain Relief, and Uristat. The generic versions are bioequivalent to the brand-name versions, meaning they contain the same active ingredient and work the same way in the body. Generic versions are available both by prescription in 100 mg and 200 mg strengths and over-the-counter in slightly lower strengths. Choosing a generic version is typically a cost-effective way to manage the symptoms of urinary discomfort. Your pharmacist can help you select the appropriate generic product based on your doctor's recommendation.
Other drugs with the same active ingredient (Phenazopyridine)